SAN DIEGO, Dec. 8 /PRNewswire/ -- TargeGen, Inc., a biopharmaceutical company focusing on the development of small molecule kinase inhibitors for the treatment of edema and angiogenesis related diseases including cardiovascular, eye diseases and cancer, today announced that the Company plans to relocate its San Diego based operations to a larger facility in mid January, 2006. TargeGen currently leases approximately 18,500 sq. ft. of laboratory and office space in the UTC area in the heart of the San Diego biotechnology community. The mid January, 2006 move will give the company access to approximately 43,000 sq. ft. of laboratory and office space in very close proximity to its current location. Effective January 16, 2006, TargeGen’s new San Diego facility will be located at 9380 Judicial Drive, San Diego, CA 92121.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO )
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to major human disease including heart attack, eye disease and cancer by targeting certain biochemical processes associated with vascular proliferation (the unwanted growth of new blood vessels) and vascular permeability (edema or leakage out of blood vessels).
TargeGen, which initiated operations in 2002, has raised more than $70M from venture capital sources. Key investors include Forward Ventures, Enterprise Partners, William Blair Capital Partners, CDP Capital Technology Ventures, BB Biotech, Hambrecht & Quist Capital Management, China Development Industrial Bank (CDIB), A.M. Pappas & Associates and others investors.
Photo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comTargeGen, Inc.
CONTACT: Peter G. Ulrich, President & CEO of TargeGen, Inc.+1-858-678-0760, or fax, +1-858-678-0762, or info@targegen.com
Web site: http://www.targegen.com/
